The European Food Safety Authority has adopted a positive scientific opinion on the safety and efficacy of Quatrefolic®, opening the way for the commercialization of the novel ingredient in Europe in the next months.
The independent panel issued the positive outcome after a thorough assessment of the safety data and bioavailability studies, a process that has lasted for nearly two and a half year, concluding that Quatrefolic may be added for nutritional purposes to food supplements as a source of folate.
This key milestone is part of the global strategic plan that started in 2010 with the approval of Quatrefolic as new dietary ingredient by FDA that has opened successfully the U.S. market, where Quatrefolic has already become a benchmark for innovation, safety and quality in the folate supplementation area.
“Gnosis’s commitment is to make Quatrefolic available in major nutritional world markets, building a reliable, scientific and innovative platform to support the fourth generation folate,” said Renzo Berna, Gnosis’ CEO. “This opinion gives us great opportunities in the market place and a strong competitive position, not only in Europe, but also in other parts of the world that is influenced by regulatory decisions taken in EU.”
Gnosis has established an extensive research and development program aimed at documenting the benefits of Quatrefolic as a dietary supplement and strives to continuously support the important benefits of reduced folates and their contribution to a healthier lifestyle.